Catalyst Pharmaceuticals (NASDAQ:CPRX) was downgraded by investment analysts at BidaskClub from a “strong-buy” rating to a “buy” rating in a research note issued to investors on Thursday.

CPRX has been the subject of a number of other research reports. Zacks Investment Research lowered shares of Catalyst Pharmaceuticals from a “hold” rating to a “sell” rating in a research report on Wednesday, October 11th. SunTrust Banks reaffirmed a “buy” rating and set a $5.00 price objective on shares of Catalyst Pharmaceuticals in a research report on Tuesday, September 5th. HC Wainwright reaffirmed a “buy” rating and set a $6.00 price objective on shares of Catalyst Pharmaceuticals in a research report on Friday, November 10th. Roth Capital set a $5.00 price objective on shares of Catalyst Pharmaceuticals and gave the company a “buy” rating in a research report on Wednesday, November 1st. Finally, Piper Jaffray Companies set a $8.00 price objective on shares of Catalyst Pharmaceuticals and gave the company a “buy” rating in a research report on Friday, December 1st. One analyst has rated the stock with a sell rating and five have issued a buy rating to the stock. The stock currently has a consensus rating of “Buy” and a consensus price target of $6.25.

Shares of Catalyst Pharmaceuticals (NASDAQ CPRX) traded down $0.17 on Thursday, hitting $4.00. 1,321,413 shares of the stock were exchanged, compared to its average volume of 2,226,653. Catalyst Pharmaceuticals has a 1-year low of $1.01 and a 1-year high of $4.51.

Several institutional investors and hedge funds have recently made changes to their positions in the company. GSA Capital Partners LLP acquired a new position in Catalyst Pharmaceuticals in the third quarter worth about $1,208,000. Crestline Management LP acquired a new position in Catalyst Pharmaceuticals in the third quarter worth about $562,000. OxFORD Asset Management LLP raised its position in Catalyst Pharmaceuticals by 60.5% in the third quarter. OxFORD Asset Management LLP now owns 138,329 shares of the biopharmaceutical company’s stock worth $344,000 after purchasing an additional 52,161 shares in the last quarter. SG Americas Securities LLC acquired a new position in Catalyst Pharmaceuticals in the third quarter worth about $144,000. Finally, California State Teachers Retirement System acquired a new position in Catalyst Pharmaceuticals in the second quarter worth about $350,000. 35.57% of the stock is owned by institutional investors and hedge funds.

COPYRIGHT VIOLATION NOTICE: This report was first reported by American Banking News and is the property of of American Banking News. If you are accessing this report on another publication, it was illegally stolen and republished in violation of US & international copyright and trademark legislation. The original version of this report can be accessed at https://www.americanbankingnews.com/2017/12/09/catalyst-pharmaceuticals-cprx-rating-lowered-to-buy-at-bidaskclub.html.

Catalyst Pharmaceuticals Company Profile

Catalyst Pharmaceuticals, Inc, formerly Catalyst Pharmaceutical Partners, Inc, is a development-stage biopharmaceutical company. The Company is focused on developing and commercializing therapies for people with rare debilitating diseases. The Company has three drugs in development: Firdapse, CPP-109 and CPP-115.

Receive News & Ratings for Catalyst Pharmaceuticals Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Catalyst Pharmaceuticals Inc and related companies with MarketBeat.com's FREE daily email newsletter.